S1 Episode 5: Small Cell Lung Cancer: What Are the First-line and Second-line Treatment Options? скачать в хорошем качестве

S1 Episode 5: Small Cell Lung Cancer: What Are the First-line and Second-line Treatment Options?

Drs Jacob Sands and Lauren Byers discuss the treatment options for patients diagnosed with small cell lung cancer and the future possibility of durable responses. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/.... The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US health care professionals. Resources FDA Approval Summary: Atezolizumab and Durvalumab in Combination With Platinum‐Based Chemotherapy in Extensive Stage Small Cell Lung Cancer https://www.ncbi.nlm.nih.gov/pmc/arti... First-line Pembrolizumab or Placebo Combined With Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-term Follow-up Results https://www.iaslc.org/iaslc-news/pres... Lurbinectedin Prescribing Information https://pp.jazzpharma.com/pi/zepzelca... Lurbinectedin as Second-line Treatment for Patients With Small-Cell Lung Cancer: A Single-Arm, Open-label, Phase 2 Basket Trial https://linkinghub.elsevier.com/retri... Trilaciclib Prescribing Information https://www.g1therapeutics.com/file.c... Primary Analysis From the Phase 2 Study of Continuous Talazoparib (TALA) Plus Intermittent Low-Dose Temozolomide (TMZ) in Patients With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer (ES-SCLC) https://ascopubs.org/doi/abs/10.1200/... Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer https://www.ncbi.nlm.nih.gov/pmc/arti... Testing Maintenance Therapy for Small Cell Lung Cancer in Patients With SLFN11 Positive Biomarker https://clinicaltrials.gov/ct2/show/N... The Role of Schlafen 11 (SLFN11) as a Predictive Biomarker for Targeting the DNA Damage Response https://www.nature.com/articles/s4141... Molecular Subtypes of Small Cell Lung Cancer: A Synthesis of Human and Mouse Model Data https://www.ncbi.nlm.nih.gov/pmc/arti... Patterns of Transcription Factor Programs and Immune Pathway Activation Define Four Major Subtypes of SCLC With Distinct Therapeutic Vulnerabilities https://www.cell.com/cancer-cell/full... Small-Cell Lung Cancer: What We Know, What We Need to Know and the Path Forward https://www.nature.com/articles/nrc.2... First-Line Atezolizumab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056... Durvalumab Plus Platinum–Etoposide Versus Platinum–Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): A Randomised, Controlled, Open-label, Phase 3 Trial https://www.thelancet.com/journals/la...